Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis

Nicoletta Del Papa(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Nicola Fracchiolla(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Gualtiero I. Colombo(Centro Cardiologico Monzino), F Fantini(University of Milan), Lorenza Mazzeo Moronetti(Ospedale Maggiore), D.P. Comina(University of Milan), Wanda Maglione(University of Milan), Claudio Vitali, Francesca Ingegnoli(University of Milan)
Arthritis & Rheumatism
April 1, 2004
10.1002/art.20116
Cited by 169

Related Papers

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis
|JAMA|2014|739
Mapping and predicting mortality from systemic sclerosis
|Annals of the Rheumatic Diseases|2017|699
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394